Dr Matthew Barter
Kat Cheung
Julia Falk
Dr Andreas Panagiotopoulos
Professor Stephen O'Brien
et al. | Dynamic chromatin accessibility landscape changes following interleukin-1 stimulation | 2021 |
|
Dr Ed Schwalbe
Dr Peter Carey
Professor Stephen O'Brien
Professor Anthony Moorman
Emilio Barretta
et al. | Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-income setting — the Blantyre experience | 2020 |
|
Dr Wendy Osborne
Professor Stephen O'Brien
| De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial | 2019 |
|
Professor Stephen O'Brien
| Trial re-investment to build better research for better impact | 2019 |
|
Professor Stephen O'Brien
| De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial | 2017 |
|
Professor Stephen O'Brien
| Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. | 2017 |
|
Dr Ed Schwalbe
Dr Kevin Windebank
Professor Stephen O'Brien
Dr Peter Carey
Professor Simon Bailey
et al. | The use of anthracyclines in the treatment of endemic Burkitt lymphoma | 2017 |
|
Professor Stephen O'Brien
| De-escalation of tyrosine kinase inhibitor therapy is safe in chronic myeloid leukaemia in durable molecular response (>= mr3 for >= 12 months): initial results in the British DESTINY study | 2016 |
|
Corrine Hedgley
Professor Stephen O'Brien
| PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase | 2015 |
|
Leanne Cork
Corinne Hedgley
Dr Wendy Osborne
Gemma Gills
Ruth Bescoby
et al. | Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia | 2015 |
|
Leanne Cork
Corrine Hedgley
Professor Stephen O'Brien
| Reliable Detection of Abl Tyrosine Kinase Domain Mutations to <1% Using NGS Data Quality Parsing and Corroboration of Overlapping Paired-End Sequences | 2015 |
|
Dr Wendy Osborne
Professor Stephen O'Brien
Corinne Hedgley
Ruth Bescoby
| SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed chronic myeloid leukaemia-2 year follow up | 2015 |
|
Dr Samuel Moses
Professor Stephen O'Brien
Dr Tobias Menne
Dr Jonathan Wallis
| Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia | 2014 |
|
Professor Stephen O'Brien
Corinne Hedgley
Lynn Alaily
Dr Wendy Osborne
| Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML | 2014 |
|
Professor Stephen O'Brien
Corinne Hedgley
Dr Wendy Osborne
| SPIRIT 2: an NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML | 2014 |
|
Professor Stephen O'Brien
| Diagnosis and treatment of chronic myeloid leukemia | 2013 |
|
Professor Stephen O'Brien
Corinne Hedgley
| Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia | 2012 |
|
Dr Samuel Moses
Professor Stephen O'Brien
Dr Tobias Menne
Dr Jonathan Wallis
| Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia | 2012 |
|
Professor Stephen O'Brien
Corinne Hedgley
| KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib | 2012 |
|
Professor Stephen O'Brien
| A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib | 2010 |
|
Professor Stephen O'Brien
Professor Julie Irving
| Analysis of BCR-ABL1 Tyrosine Kinase Domain Mutations In Primitive Chronic Myeloid Leukemia Cells Identifies a Unique Mutator Phenotype | 2010 |
|
Professor Stephen O'Brien
| KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib | 2010 |
|
Dr Michelle Muller
Professor Stephen O'Brien
| Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) | 2010 |
|
Professor Stephen O'Brien
| A Gene Expression Signature of CD34+Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance | 2009 |
|
Professor Stephen O'Brien
| Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase | 2009 |
|
Professor Stephen O'Brien
| High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial | 2009 |
|
Professor Stephen O'Brien
| International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib | 2009 |
|
Professor Stephen O'Brien
| Seven year follow-up of the International Randomized Study of Interferon Versus STI571 (IRIS) demonstrates durable efficacy and long-term safety of imatinib in patients (pts) with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP) | 2009 |
|
Professor Stephen O'Brien
| Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia | 2009 |
|
Professor Stephen O'Brien
| Steady-State Imatinib Trough Levels as Well as Dose Interruptions Are Associated with Clinical Response (CCyR and MMR) and Adverse Events (AEs) in Patients with Chronic Myeloid Leukemia (CML) Receiving IM as Frontline Therapy | 2009 |
|
Professor Stephen O'Brien
| Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment | 2008 |
|
Professor Stephen O'Brien
| Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation | 2008 |
|
Professor Stephen O'Brien
| Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study | 2008 |
|
Jean Norden
Professor Stephen O'Brien
| Improved single nucleotide polymorphisms detection using conjugated polymer/surfactant system and peptide nucleic acid | 2008 |
|
Professor Stephen O'Brien
| International Randomized Study of Interferon Versus ST1571 (IRIS) 7-year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (IM) | 2008 |
|
Professor Stephen O'Brien
| On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia | 2008 |
|
Dr Michelle Muller
Professor Stephen O'Brien
| Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP) | 2008 |
|
Dr Feng Lin
Professor Stephen O'Brien
| An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR | 2007 |
|
Professor Stephen O'Brien
| Cytogenetic response and discontinuations from IRIS study with long-term imatinib therapy in newly diagnosed Ph+ chronic myelogenous leukemia | 2007 |
|
Professor Stephen O'Brien
| Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP) | 2007 |
|
Professor Stephen O'Brien
| Imatinib plasma concentration and sokal risk score are independently prognostic for complete cytogenetic response (CCyR) in patients with chronic phase chronic myeloid leukemia (CML-CP) | 2007 |
|
Professor Stephen O'Brien
| IRIS 6-year follow-up: Sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), treated with imatinib | 2007 |
|
Professor Stephen O'Brien
| Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance | 2007 |
|
Professor Stephen O'Brien
| Nilotinib is safe and effective in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib resistance or intolerance | 2007 |
|
Professor Alan Boddy
Julieann Sludden
Melanie Griffin
Professor Herbie Newell
Professor Stephen O'Brien
et al. | Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia | 2007 |
|
Dr Udo Holtick
Dr Scott Marshall
Professor Stephen O'Brien
Professor Matthew Collin
| Potent graft-versus-leukemia effect in BCR/ABL negative chronic myelogenous leukemia | 2007 |
|
Professor Stephen O'Brien
| Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy | 2007 |
|
Professor Stephen O'Brien
| A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) | 2006 |
|
Professor Stephen O'Brien
| A phase II study of nilotinib a novel tyrosine kinase inhibitor administered to imatinib-resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP) | 2006 |
|
Professor Stephen O'Brien
| Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - An analysis of IRIS study data | 2006 |
|
Professor Stephen O'Brien
| Declining rates of adverse events (AEs), rare occurrence of serious AEs (SAEs), and no unexpected long-term side effects at 5 years in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) initially treated with imatinib (IM) in the international randomized study of interferon vs STI571 (IRIS) | 2006 |
|
Professor Stephen O'Brien
| Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate | 2006 |
|
Professor Stephen O'Brien
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia | 2006 |
|
Professor Stephen O'Brien
| Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study | 2006 |
|
Professor Stephen O'Brien
| Outcomes by cytogenetic and molecular response at 12 and 18 months of imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) in the IRIS trial | 2006 |
|
Professor Stephen O'Brien
| Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials | 2006 |
|
Dr Lucy Crossman
Professor Stephen O'Brien
Dr Peter Middleton
| A gene polymorphism within the kinase domain of BCR-ABL and its effects on sensitivity to tyrosine kinase inhibitors | 2005 |
|
Dr Lucy Crossman
Professor Stephen O'Brien
Dr Peter Middleton
| A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib | 2005 |
|
Jill Crossman
Professor Stephen O'Brien
| Gene expression profiling of CML CD34+ cells prior to imatinib therapy reveals differences between patients with and without subsequent complete cytogenetic response | 2005 |
|
Professor Stephen O'Brien
| Chronic myelogenous leukemia and myeloproliferative disease | 2004 |
|
Dr Lucy Crossman
Professor Stephen O'Brien
| Clinical results with imatinib in chronic myeloid leukaemia | 2004 |
|
Dr Lucy Crossman
Professor Stephen O'Brien
| Imatinib therapy for chronic myeloid leukemia | 2004 |
|
Professor Julie Irving
Professor Stephen O'Brien
Dr Anne Lennard
Lynne Minto
Dr Feng Lin
et al. | Use of Denaturing HPLC for Detection of Mutations in the BCR-ABL Kinase Domain in Patients Resistant to Imatinib | 2004 |
|
Dr Feng Lin
Professor Stephen O'Brien
| An international study to standardize the detection of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR | 2003 |
|
Professor Stephen O'Brien
| Designer drugs for fusion genes: imatinib and chronic myeloid leukaemia | 2003 |
|
Professor Julie Irving
Professor Stephen O'Brien
Dr Anne Lennard
Dr Feng Lin
Dr Andrew Hall
et al. | The use of denaturing high-performance liquid chromatography (DHPLC) for the detection of mutations in the bcr-abl oncogene in patients resistant to imatinib | 2003 |
|
Professor Stephen O'Brien
| Continuous oral lonafarnib (Sarasar (TM)) for the treatment of patients with advanced hematologic malignancies: A phase II study | 2002 |
|
Dr John Byrne
Professor Stephen O'Brien
Dr Anne Lennard
| Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group. | 2002 |
|
Professor Stephen O'Brien
| Phase I study of continuous oral administration of lonafarnib (Sarasar (TM)) in patients with advanced hematologic malignancies | 2002 |
|
Professor Stephen O'Brien
| Use of imatinib mesylate in patients with CML in chronic phase resistant to interferon-alfa: Factors defined at start of therapy that predict disease progression and survival | 2002 |
|
Professor Stephen O'Brien
| A pharmacokinetic interaction of Glivec (R) and Simvastatin, a cytochrome 3A4 substrate, in patients with chronic myeloid leukemia | 2001 |
|
Gavin Cuthbert
Julie Freeman-Edward
Dr Anne Lennard
Professor Stephen O'Brien
Dr Nicholas Bown
et al. | Der(9) deletions and response to STI571(Glivec (R)) treatment in chronic phase CML patients. | 2001 |
|
Dr Annette Neylon
Professor Stephen O'Brien
Dr Peter Middleton
| IL-4 gene polymorphism and outcome following sibling allogeneic bone marrow transplant | 2001 |
|
Professor Stephen O'Brien
| Imatinib for chronic myeloid leukaemia: a NICE mess | 2001 |
|
Professor Stephen O'Brien
| Imatinib for chronic myeloid leukaemia: A NICE mess [multiple letters] | 2001 |
|
Dr Annette Neylon
Professor Stephen O'Brien
| Improving the management of chronic myeloid leukaemia | 2001 |
|
Professor Stephen O'Brien
Susan Tremble
| PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia | 2001 |
|
Dr Feng Lin
Professor Stephen O'Brien
Dr Anne Lennard
| Response of chronic phase CML patients to STI571 therapy assessd by quantitative real time PCR | 2001 |
|
Dr Annette Neylon
Professor Stephen O'Brien
Dr Peter Middleton
| The correlation of cytokine gene polymorphisms with outcome in chronic phase CML patients undergoing allogeneic BMT | 2001 |
|
Denise Howel
Professor Stephen O'Brien
Dr David Chinn
Professor Peter Blain
| Upper aerodigestive tract cancers in former employees at an iron and steel works | 2001 |
|
